The S-898270 Phase 1 study
Latest Information Update: 18 Feb 2026
At a glance
- Drugs S 898270 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
Most Recent Events
- 18 Feb 2026 New trial record
- 10 Feb 2026 According to Cumulus Neuroscience media release, the S-898270 Phase 1 study is ongoing and enrolling healthy controls in early 2026.